HomeCompareBVNRY vs MAIN

BVNRY vs MAIN: Dividend Comparison 2026

BVNRY yields 20.15% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $42.86M in total portfolio value
10 years
BVNRY
BVNRY
● Live price
20.15%
Share price
$9.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.3K
Annual income
$2.34
Full BVNRY calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — BVNRY vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNRYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNRY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNRY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNRY
Annual income on $10K today (after 15% tax)
$1,712.85/yr
After 10yr DRIP, annual income (after tax)
$1.99/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, MAIN beats the other by $30,445,593.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNRY + MAIN for your $10,000?

BVNRY: 50%MAIN: 50%
100% MAIN50/50100% BVNRY
Portfolio after 10yr
$21.45M
Annual income
$17,909,175.17/yr
Blended yield
83.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

BVNRY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
6.6
Piotroski
8/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNRY buys
0
MAIN buys
0
No recent congressional trades found for BVNRY or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNRYMAIN
Forward yield20.15%6.91%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%72.7%
Portfolio after 10y$23.3K$42.89M
Annual income after 10y$2.34$35,818,348.00
Total dividends collected$2.1K$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusHoldHold

Year-by-year: BVNRY vs MAIN ($10,000, DRIP)

YearBVNRY PortfolioBVNRY Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,708$1,007.56$12,434$1,193.51$726.00MAIN
2$13,078$551.22$16,255$2,280.05$3.2KMAIN
3$14,282$287.74$22,851$4,580.08$8.6KMAIN
4$15,428$146.83$35,577$9,892.59$20.1KMAIN
5$16,582$74.12$63,653$23,664.70$47.1KMAIN
6$17,780$37.23$136,601$65,054.52$118.8KMAIN
7$19,043$18.65$368,044$214,504.02$349.0KMAIN
8$20,386$9.34$1,301,668$887,987.40$1.28MMAIN
9$21,817$4.67$6,288,483$4,825,407.47$6.27MMAIN
10$23,347$2.34$42,886,603$35,818,348.00$42.86MMAIN

BVNRY vs MAIN: Complete Analysis 2026

BVNRYStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNRY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this BVNRY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNRY vs SCHDBVNRY vs JEPIBVNRY vs OBVNRY vs KOBVNRY vs ARCCBVNRY vs HTGCBVNRY vs GBDCBVNRY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.